NetMind.AI plans to start NMT buyback in the future to enhance the utility of tokens
According to BlockBeats news, on October 28, NetMind.AI CEO Kai Zou posted on the social media platform to announce the recent progress and future prospects of the project:
1. Continuous innovation of products and functions: As always, we will continue to upgrade new functions for our products and always stand at the forefront of technology. The newly designed website will be launched soon.
2. Expansion of customer base and strategic partners: More customers have been added, more cooperation has been reached with leading technology companies, consulting work has increased, and AI models have been further optimized.
3. Team expansion: The team is growing rapidly. A dedicated business development team has been established and we continue to recruit professionals in the fields of research engineers, product development and business development.
4. Improvement of research work: There has been a significant improvement in research output, and more research work is transformed into more innovative functions and cutting-edge technologies, which NetMind will exclusively implement and apply.
5. Establish the NetMind program: Provide more support to startups, more NMT computing resources will be used for their research and development, and the entire ecosystem is expected to gain benefits and achievements in the future.
6. Enhance the utility of the token: Simple and clear, it is the buyback plan. Wider use of NMT is planned through the NetMind initiative.
7. NetMind Agent Platform Coming Soon: All agents and multi-agent systems will run on NetMind Power, leveraging NMT enhancements and enabling integration capabilities in decentralized infrastructure.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tom Lee Says Yields Below 5% Mean the AI Selloff Is Nearly Over
Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) will be listed on Nasdaq tonight! IPO priced at $18 per share, aiming to raise $317.5 millions.
Lycia will issue 17.64 million shares at a price of $18 per share to raise $317.5 million.
Citi is bullish on Palantir (PLTR.US): U.S. government and commercial businesses jointly drive growth, Q3 revenue is expected to exceed expectations again
Citigroup maintains its "Buy" rating on Palantir and raises the target price from $245 to $250.
Despite its stock price being halved, Goldman Sachs maintains a Buy rating: Holding $10 billions in orders, CoreWeave (CRWV) faces a major test with several billions in financing
As a core manufacturer of AI computing power infrastructure, CoreWeave (CRWV.US) holds orders worth tens of billions and its business is expanding rapidly. However, capital expenditure pressure and financing gaps have become the main concerns of the market.
Crypto prices
More
